EUCTR2011-000987-92-SK
Active, not recruiting
Phase 1
Open-label, phase II, single arm study to evaluate the safety, immunogenicity, pharmacokinetics and efficacy of recombinant human C1 inhibitor for the treatment of acute attacks in pediatric patients with hereditary angioedema, from 2 up to and including 13 years of age - Safety of Ruconest in 2-13 year old HAE patients
ConditionsAttacks associated with hereditary angioedema (HAE) in pediatric population 2-13 years of age.MedDRA version: 17.0Level: PTClassification code 10019860Term: Hereditary angioedemaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
DrugsRuconest
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Attacks associated with hereditary angioedema (HAE) in pediatric population 2-13 years of age.
- Sponsor
- Pharming Technologies B.V.
- Enrollment
- 20
- Status
- Active, not recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •From 2 up to and including 13 years of age
- •Clinical and laboratory confirmed diagnosis of HAE (baseline C1INH activity \<50% of normal)
- •Signed written informed consent (parental permission) signed by the legal guardian(s)
- •Clinical symptoms of an acute HAE attack
- •Onset of eligible symptoms within 5 hours from the moment at which medical evaluation to determine eligibility has occurred
- •IS score for at least one anatomical location at the time of initial evaluation of at least 3 (moderate severity or greater) without signs of spontaneous regression
- •24h or more have passed since the patient’s last study treatment
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 20
- •F.1\.2 Adults (18\-64 years) no
Exclusion Criteria
- •A diagnosis of acquired C1INH deficiency (AAE)
- •A medical history of allergy to rabbits or rabbit\-derived products (including rhC1INH, antisera), or positive anti\-rabbit epithelium (dander) IgE test (cut off\>0\.35 kU/L in ImmunoCap® assay (Phadia, Sweden) or equivalent)
- •Treatment with investigational drug in another clinical study in the last 30 days
- •Any clinical significant abnormality in the physical examination and/or the routine laboratory assessments, that in the opinion of the Investigator makes the patient unsuitable for participation in the study
- •Any condition or treatment that in the opinion of the investigator might interfere with the evaluation of the study objectives
- •Any changes since screening that would exclude patient based on above exclusion criteria.
- •10 HAE attacks were previously treated with study medication.
- •Suspicion for an alternate explanation of the symptoms other than an acute HAE attack.
- •Use of any disallowed concomitant medication since onset of acute HAE attack
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Open-label, phase II, single arm study to evaluate the safety, immunogenicity, pharmacokinetics and efficacy of recombinant human C1 inhibitor for the treatment of acute attacks in pediatric patients with hereditary angioedema, from 2 up to and including 13 years of ageEUCTR2011-000987-92-DEPharming Technologies B.V.20
Active, not recruiting
Phase 1
Safety of Ruconest in children with HAEAttacks associated with hereditary angioedema (HAE) in pediatric population 2-13 years of age.MedDRA version: 18.1Level: PTClassification code 10019860Term: Hereditary angioedemaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]EUCTR2011-000987-92-HUPharming Technologies B.V.20
Active, not recruiting
Phase 1
Safety of Ruconest in children with HAEAttacks associated with hereditary angioedema (HAE) in pediatric population 2-13 years of age.MedDRA version: 18.1Level: PTClassification code 10019860Term: Hereditary angioedemaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]EUCTR2011-000987-92-CZPharming Technologies B.V.20
Active, not recruiting
Phase 1
Open-label study to evaluate the safety, and efficacy of recombinant human C1 inhibitor for the treatment of acute attacks in pediatric patients with hereditary angioedema, from 2 up to and including 13 years of ageHereditary angioedema (HAE). Hereditary angioedema is characterized by angioedema localized and recurrent caused by by uncontrolled activation of the Complement systems due to congenital deficiency of Functional C1 inhibitor (C1INH). Reports in Medical the literature suggests that C1INH replacement therapy with human plasma-derived represents a safe and effective acute attacks of HAMedDRA version: 14.1Level: PTClassification code 10019860Term: Hereditary angioedemaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2011-000987-92-ITPHARMING TECHNOLOGIES B.V.20
Active, not recruiting
Not Applicable
Phase 2, open label, single arm study to evaluate the efficacy, safety, tolerability and pharmacokinetics of CP-675,206 in patients with advanced refractory and/or relapsed melanoma - N/AEUCTR2005-002826-70-DEPfizer Pharma GmbH215